John was Head of Medicinal Chemistry for 20 years at Fisons, Vice President of Preclinical R&D in Astra Charnwood for 4 years and Vice President of Drug Discovery at AstraZeneca Charnwood for 9 years.
As VP of AstraZeneca Charnwood he delivered 35 candidate drugs, most recently in the respiratory area. Currently 2 Charnwood compounds are in Phase III and 4 in Phase II. Brilinta, a potential blockbuster for thrombotic disorders, achieved Marketing approval in Europe and final FDA approval on 20th July 2011.
A Fellow of the Royal Society of Chemistry and Member of the American Chemical Society John served on several professional and academic advisory committees and was awarded an honorary D.Sc. from Loughborough University.
He retired from AstraZeneca in July 2008 and is now Director of JD International Consulting Ltd. His consultancies cover most aspects of Drug Discovery and Early Development in most therapy areas and in all types of organisations within 9 different countries.